<DOC>
	<DOCNO>NCT01075282</DOCNO>
	<brief_summary>The purpose study determine LY2189265 effective reduce hemoglobin A1c ( HbA1c ) safe , compare Insulin Glargine participant Type 2 Diabetes . Participants must also take metformin glimepiride .</brief_summary>
	<brief_title>A Study Participants With Type 2 Diabetes Mellitus ( AWARD-2 )</brief_title>
	<detailed_description>Rescue therapy refers 1 2 type additional therapy , give different reason : additional therapeutic intervention participant develop persistent , severe hyperglycemia despite full compliance assign therapeutic regimen , initiation alternative antihyperglycemic medication follow study drug discontinuation . Participants receive rescue therapy include analysis population , measurement obtain prior begin rescue therapy include specify efficacy analysis .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Glimepiride</mesh_term>
	<mesh_term>Dulaglutide</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>Type 2 Diabetes well control 1 , 2 , 3 oral antidiabetic medication ( least one must metformin and/or sulfonylurea ) 1 . Glycosylated hemoglobin ( HbA1c ) great equal 7 less equal 11 take 1 oral antidiabetic medication 2 . HbA1c great equal 7 less equal 10 2 3 oral antidiabetic medication Accept treatment metformin glimepiride throughout study , per protocol Willing inject subcutaneous medication weekly LY2189265 daily Insulin Glargine . Stable weight 3 month prior screen Body mass index ( BMI ) 23 45 kilogram per square meter ( kg/m^2 ) Females child bear potential must test negative pregnancy screen serum pregnancy test willing use reliable method birth control study 1 month follow last dose study drug Type 1 Diabetes HbA1c equal less 6.5 randomization Chronic insulin use Taking drug promote weight loss prescription counter Taking systemic steroid great 14 day except topical , eye , nasal , inhaled History Heart Failure New York Heart Classification III IV , acute myocardial infarction , stroke within 2 month screen Gastrointestinal ( GI ) problem diabetic gastroparesis bariatric surgery ( stomach staple ) chronically take drug directly affect GI motility Hepatitis liver disease ALT ( alanine transaminase ) great 3.0 upper normal limit Acute chronic pancreatitis form Renal disease ( kidney ) serum creatinine great equal 1.5 milligram per deciliter ( mg/dL ) males great equal 1.4 mg/dL female , creatinine clearance le 60 milliliter per minute ( ml/min ) History ( include family ) type 2A 2B Multiple Endocrine Neoplasia ( MEN 2A 2B ) medullary ccell hyperplasia thyroid cancer A serum calcitonin great equal 20 picograms per milliliter ( pcg/ml ) screen Significant active autoimmune disease Lupus Rheumatoid Arthritis History active malignancy except skin situ cervical prostate cancer within last 5 year Sickle cell , hemolytic anemia , hematological condition may interfere HbA1c test Organ transplant except cornea Have enrol another clinical trial within last 30 day Have previously sign informed consent participate LY2189265 study Have take glucagonlike peptide 1 ( GLP1 ) receptor agonist within 3 month prior screen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
</DOC>